The total number of treatments avoided increased from 10,095 children after introduction of vaccine to 30,286 children in fifth year. ConClusions: The introduction of Malaria vaccine for children younger than 5 years by Global fund in Rwanda may be affordable when compared to the amount money spent on treatment.
the social perspective was chosen for the Netherlands and the third-party payer perspective for the UK. In the sensitivity analyses the robustness of the results were tested and various additional scenario analyses were conducted. Results: After screening titles, abstracts and full-text papers only three (out of sixteen) studies for the Netherlands and six (out of 25) studies for the UK remained. In the base case analysis for the Netherlands (mean incidence: 3.4%; Vaccine Efficacy (VE):50%), EJPs of V5.36 (95% CI,-0.09-16.95) and V21.27 (95% CI, 9.05-45.62) were found for the acquisition costs, corresponding with the lower and higher WTP respectively. In the base case analysis for the UK (mean incidence: 6.6%; VE:50%), EJPs of £16.53 (95% CI, 7.67-27.5) and £42.72 (95% CI, 24.90-65.76) were found for the acquisition costs corresponding the lower and higher WTP respectively. Conclusions: An RSV vaccine may be cost-effective in both the Netherlands and the UK, depending on the VE, vaccine price and the RSV incidence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.